N

NovaBridge Biosciences
D

NBP

3.97000
USD
-0.14
(-3.29%)
مغلق
حجم التداول
30,146
الربح لكل سهم
-0
العائد الربحي
-
P/E
-9
حجم السوق
457,606,234
المقالات

العنوان: NovaBridge Biosciences

القطاع: Healthcare
الصناعة: Biotechnology
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).